BioVentures — 2019 Investments

1 investments dated 2019 · listed companies and verified rows first · show all

Avirmaxavirmax.comin 𝕏Nov 2019SEC filinghigh confidence

Avirmax is a preclinical-stage biopharmaceutical company developing AAV-based genetic medicines to treat chronic and degenerative ocular diseases.

BiotechDeep TechMedical DevicesHayward, US

Yu Fang(Director of the Issuer)Qianye Karen Liu(Director of the Issuer)Haifeng Chen(Director and Treasurer of the Issuer)Shengjiang Liu(Executive Officer, Director)Nancy Chang(Director of the Issuer)

Board seatQianye Karen LiuYu Fang· per SEC Form D · $10M raise · filed Nov 2019

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.